Viking Therapeutics Inc (VKTX) concluded trading on Wednesday at a closing price of $23.10, with 8.27 million shares of worth about $190.97 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -63.34% during that period and on April 09, 2025 the price saw a gain of about 15.62%. Currently the company’s common shares owned by public are about 111.57M shares, out of which, 108.95M shares are available for trading.
Stock saw a price change of -10.05% in past 5 days and over the past one month there was a price change of -12.90%. Year-to-date (YTD), VKTX shares are showing a performance of -42.59% which decreased to -69.56% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $19.58 but also hit the highest price of $81.86 during that period. The average intraday trading volume for Viking Therapeutics Inc shares is 4.63 million. The stock is currently trading -12.43% below its 20-day simple moving average (SMA20), while that difference is down -19.34% for SMA50 and it goes to -52.43% lower than SMA200.
Viking Therapeutics Inc (NASDAQ: VKTX) currently have 111.57M outstanding shares and institutions hold larger chunk of about 73.47% of that.
The stock has a current market capitalization of $2.59B and its 3Y-monthly beta is at 0.89. It has posted earnings per share of -$1.01 in the same period. It has Quick Ratio of 33.09 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VKTX, volatility over the week remained 14.39% while standing at 8.04% over the month.
Analysts are in expectations that Viking Therapeutics Inc (VKTX) stock would likely to be making an EPS of -0.31 in the current quarter, while forecast for next quarter EPS is -0.36 and it is -2.07 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.42 which is -0.16 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.26 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -55.67% while it is estimated to decrease by -34.41% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on April 08, 2025 offering a Neutral rating for the stock and assigned a target price of $30 to it. Coverage by Scotiabank stated Viking Therapeutics Inc (VKTX) stock as a Sector outperform in their note to investors on February 13, 2025, suggesting a price target of $102 for the stock. Stock get a Buy rating from B. Riley Securities on November 22, 2024.
